Tandem Diabetes Care Inc
NASDAQ:TNDM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (46.9), the stock would be worth $-6.54 (132% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -148.2 | $20.68 |
0%
|
| 3-Year Average | 46.9 | $-6.54 |
-132%
|
| 5-Year Average | 64.7 | $-9.03 |
-144%
|
| Industry Average | 16.1 | $-2.24 |
-111%
|
| Country Average | 13.3 | $-1.86 |
-109%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
1.4B USD | -148.2 | -7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170B USD | 56.1 | 59.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
160.6B USD | 16.8 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.1B USD | 25 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.5B USD | 14.8 | 23.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
97.4B USD | 21.5 | 33.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.6B EUR | 13.4 | 19.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 29 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 37.8 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 13 | 25.1 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.9B USD | 16 | 15.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Tandem Diabetes Care Inc
Glance View
Tandem Diabetes Care Inc., a prominent figure in the healthcare sector, has carved out a notable niche with its innovative diabetes management solutions. Founded in 2006 and headquartered in San Diego, California, the company has become a leader in providing advanced insulin pump technologies. Central to Tandem’s business model is their flagship product, the t:slim X2 Insulin Pump, a sleek and user-friendly device praised for its ease of use and functionality. Through meticulous engineering and design, Tandem has positioned itself at the forefront of modern diabetes management by enhancing user experience and integrating advanced technologies such as continuous glucose monitoring (CGM) compatibility, making diabetes care more dynamic and responsive. Revenue for Tandem Diabetes Care primarily flows from the sale of these insulin pumps, along with associated supplies and accessories, which are crucial for ongoing diabetes management. The company also generates income through software and technology upgrades. By offering a subscription-based model, Tandem ensures steady revenue from the continual acquisition of consumables and technology updates, fostering customer loyalty and long-term engagement. Their commitment to innovation and patient-centric solutions has not only allowed them to tap into a growing market of diabetes patients seeking improved quality of life but has also strengthened their competitive edge in a rapidly evolving healthcare landscape.
